financing

News

Corxel's raises $287m for obesity drug, and other financings

Our latest biofinancing round-up sees big rounds for Corxel and Caldera, with Mendra, Think Bio, Exciva, Cytotheryx, and Infinitopes also raising cash

News

AgomAb and SpyGlass push the IPO button

Glimmers of a renewal of biotech IPO activity in 2026 have continued with the news that AgomAb and SpyGlass Pharma are sizing up investor interest.

News

Perlmutter's Eikon follows the IPO trail

Two more biotechs have joined the Nasdaq IPO queue, namely Roger Perlmutter's cancer biotech Eikon and hair loss drug developer Veradermics.

News

$100 bill with missing puzzle pieces to be inserted

Parabilis scores $305m in bumper biofinancing week

Money has flooded into biotechs this week, with Parabilis raising $305m and five other start-ups closing nine-figure private rounds.

News

Aktis Oncology files much-expanded IPO

Aktis Oncology has filed its IPO, seeking to raise up to around $210 million in what could be the first biotech listing on the Nasdaq in 2026.

News

Ambros' $125m for pain disorder drug, and other financings

Our latest crop of biofinancings has nine-figure rounds for Ambros, Atavistik, Orum, and Addition, with Link Cell and Aeovian also raising new funds.

Corxel's raises $287m for obesity drug, and other financings

AgomAb and SpyGlass push the IPO button

Perlmutter's Eikon follows the IPO trail

Parabilis scores $305m in bumper biofinancing week

Aktis Oncology files much-expanded IPO

Ambros' $125m for pain disorder drug, and other financings

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

financing

Editor's Picks